Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCSL Ltd

CSL Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
202.04 AUD -0.36 ( 0.18%)
Last update at 2026-11-06T06:17:00Z
VOLUME
1316473
Market Cap
97128.58M

Momentum Score

…

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
199.43
Low
202.37
High
52 Week Price Range
88.83
Low
203.13
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

CSL Ltd is a global biopharmaceutical company that develops and manufactures plasma-derived therapies and vaccines through a vertically integrated plasma collection and production network. Major long-term growth drivers include aging populations and rising demand for immunoglobulin and rare-disease treatments, expansion of plasma collection capacity and ongoing R&D, and investors may find the company attractive due to its market-leading portfolio, recurring revenue model and global scale.

Material investment risks include reliance on plasma supply and complex manufacturing capacity, regulatory and approval risks that could delay launches, and pricing or competitive pressures that investors should monitor.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
202.40
Dividend Yield
1.48%
Revenue TTM
15797.00M
Revenue Per Share
32.77
Gross Profit TTM
8075.00M
Debt / Equity
0.74
ROE
-15.84%
Net Debt
9378.94M
ROCE
14.49%
Diluted EPS TTM
-7.90

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -4176.73M 3724.00M 3375.00M 2663.00M 2779.60M
Minority interest 407.00M -134.00M -72.00M -50.00M -
Net income -2635.62M 3002.00M 2642.00M 2194.00M 2254.70M
Selling general administrative 2611.00M 1000.00M 856.00M 1086.00M 688.00M
Selling and marketing expenses - 1616.00M 1573.00M 1454.00M 960.70M
Gross profit 7654.44M 7951.00M 7561.00M 6708.00M 5663.50M
Reconciled depreciation 1041.00M 1017.00M 938.00M 831.00M 542.50M
Ebit 4099.06M 4117.00M 3795.00M 3071.00M 2922.40M
Ebitda 5162.92M 5134.00M 4733.00M 3902.00M 3464.90M
Depreciation and amortization 1063.85M 1017.00M 938.00M 831.00M 542.50M
Operating income 4099.06M 2959.00M 2764.00M 4884.05M 4239.47M
Other operating expenses 11943.59M 12471.00M 11926.00M 3989.22M 2951.84M
Interest expense 439.44M 393.00M 420.00M 408.00M 142.80M
Tax provision -1101.00M 588.00M 661.00M 419.00M 524.90M
Interest income 30.00M 38.00M 39.00M 406.00M 17.40M
Net interest income -405.00M -410.00M -437.00M -406.00M -160.60M
Income tax expense -1125.17M 588.00M 661.00M 419.00M 524.90M
Total revenue 16042.65M 15430.00M 14690.00M 13174.00M 10493.10M
Total operating expenses 3555.38M 4992.00M 4797.00M 4606.00M 3347.40M
Cost of revenue 8388.20M 7479.00M 7129.00M 6466.00M 4829.60M
Total other income expense net -8275.79M 765.00M 611.00M 136.00M 81.60M
Net income from continuing ops -2986.00M 3136.00M 2714.00M 2244.00M 2254.70M
Net income applicable to common shares - 3002.00M 2642.00M 2194.00M 2254.70M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 33631.43M 39404.00M 56931.95M 36234.00M 28346.00M
Intangible assets 4597.01M 8120.00M 8267.00M 8367.00M 1450.80M
Other current assets 338.85M - 568.99M 9.00M 4.20M
Total liab 17331.49M 17997.00M 27882.01M 18408.00M 13768.50M
Total stockholder equity 14790.59M 19335.00M 25998.35M 15786.00M 14577.50M
Other current liab 3371.54M - 4436.62M 5687.30M 9437.77M
Common stock 4383.10M - 557.00M 517.00M 483.80M
Capital stock -120.00M 574.00M 557.00M 517.00M 483.80M
Retained earnings 13692.07M 17744.00M 23975.44M 14621.00M 13503.40M
Other liab - - - 2628.00M 1496.50M
Good will 6362.24M 8065.00M 12097.03M 8079.00M 1187.30M
Other assets - - 0.00M 908.00M 938.60M
Cash 1512.35M 2157.00M 2481.10M 1548.00M 10436.40M
Total current liabilities 5351.68M 4815.00M 7411.84M 4608.00M 7108.20M
Current deferred revenue - - 263.53M -2954.30M -7415.37M
Net debt 9378.94M 7679.00M 15761.02M 10679.00M -778.60M
Short term debt 1141.51M - 1413.49M 1055.00M 4494.00M
Short long term debt 1003.00M 695.00M 848.00M 964.00M 4420.50M
Short long term debt total 10891.28M - 18242.12M 12227.00M 9657.80M
Other stockholder equity -4503.05M - -557.00M -29492.00M -26783.81M
Property plant equipment - - - 9352.00M 8308.60M
Total current assets 11826.88M 11850.00M 16123.38M 9259.00M 16460.70M
Long term investments 154.00M 203.00M 163.00M 173.00M 402.90M
Net tangible assets - - - -660.00M 11939.40M
Short term investments - - - 9.00M 4.20M
Net receivables 3351.55M 2283.00M 4143.15M 1905.00M 1483.20M
Long term debt 8380.00M 9141.00M 9671.00M 9564.00M 3862.50M
Inventory 6624.13M 6466.00M 8930.15M 5466.00M 4333.00M
Accounts payable 838.64M 808.00M 1298.20M 820.00M 591.80M
Accumulated other comprehensive income 1218.47M - 2022.91M 648.00M 590.30M
Non currrent assets other 92.96M - 8156.51M 102.00M 18.20M
Non current assets total 21804.55M 27554.00M 40808.56M 26975.00M 11885.30M
Capital lease obligations 1513.00M 1662.00M 1664.00M 1699.00M 1374.80M
Long term debt total - - - 11172.00M 5163.80M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments 4.00M -850.00M -1259.00M -11843.00M -387.70M
Change to liabilities - - - 197.00M 212.30M
Total cashflows from investing activities -1298.90M -850.00M -1259.00M -11843.00M -1636.10M
Net borrowings -470.00M -735.00M 41.00M 1661.00M 3723.70M
Total cash from financing activities -2890.09M -2241.00M -1284.00M 456.00M 7675.90M
Change to operating activities - - - 51.00M -102.70M
Net income -2635.62M 3002.00M 4031.82M 3294.07M 3266.14M
Change in cash -766.93M 514.00M 134.00M -8825.00M 8604.30M
Begin period cash flow 2279.27M 1643.00M 1509.00M 10334.00M 1730.10M
End period cash flow 1512.34M 2157.00M 1643.00M 1509.00M 10334.40M
Total cash from operating activities 3589.11M 3561.00M 2812.39M 3905.14M 3807.84M
Issuance of capital stock 30.00M 17.00M 40.00M 34.00M 4988.40M
Depreciation 1063.85M 1017.00M 1431.43M 1088.52M 647.43M
Other cashflows from investing activities -3.07M -381.00M -689.92M -10151.00M -0.70M
Dividends paid 1443.00M -1434.00M -1266.00M 1239.00M 1038.70M
Change to inventory -477.25M - -1190.32M -1361.77M -1306.46M
Change to account receivables -574.34M - -1168.95M 42.04M -65.18M
Sale purchase of stock -739.90M 17.00M 40.00M 2539.00M 4092.70M
Other cashflows from financing activities -257.53M -89.00M -99.00M -80.00M -50.10M
Change to netincome - - - 207.00M 668.80M
Capital expenditures 660.18M 1017.00M 1258.00M 1692.00M 1247.70M
Change in working capital -627.48M -1914.00M -1161.99M -1319.73M -1371.63M
Stock based compensation - - - 208.69M 169.46M
Other non cash items 5788.35M 3561.00M 3974.38M -477.45M -105.73M
Free cash flow 2928.92M 2544.00M 1506.00M 2213.14M 2560.14M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86
PYC
PYC Therapeutics Ltd		 -0.05
2.59%		 1.88 - 12.00 73.11 2.63 25.02 -8.41

Profile*

CSL Ltd

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

655 Elizabeth Street, Melbourne, VIC, Australia, 3000

61 3 9389 1911

https://www.csl.com

29000

Name Title Year Born
Mr. Paul R. Perreault B.A. MD, CEO & Exec. Director 1957
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI Chief Financial Officer 1965
Dr. Paul F. McKenzie Ph.D. Chief Operating Officer 1966
Mr. Mark Dehring Head of Investor Relations NA
Mr. Gregory Boss B.S., BS(Hons), J.D. Exec. VP of Legal & Group Gen. Counsel 1961
Christina Hickie Sr. Mang. of Communications NA
Ms. Elizabeth Walker B.A., M.S. Exec. VP & Chief HR Officer 1970
Dr. Karen Etchberger Exec. VP of Quality & Bus. Services 1958
Dr. Wilfried Freudenberg Department Head of Albumin & Immunoglobulins Production NA
Ms. Jemimah Brennan Head of Communications - Asia Pacific NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…